Sevilla

• Study of BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma Ended recruitment
  2022-500687-35-00 9 2023-04-04 Refractory Mantle Cell Lymphoma
• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Met … Ended recruitment
  2023-505816-39-00 4 2023-04-04 Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carci
• (Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended recruitment
  2022-500637-80-00 5 2023-03-28 gastrointestinal stromal tumor
• A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c … Ended recruitment
  2024-511169-12-00 5 2023-03-28 Non-Small Cell Lung Cancer
• "Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures " Ended recruitment
  2023-506841-52-00 5 2023-03-22 partial-onset (focal) seizures
• A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid Tu … Ended recruitment
  2023-509504-15-00 4 2023-03-20 HR-positive HER2-negative metastatic/advanced BC
• A Phase 2a Study to Evaluate the Safety and Efficacy of MK-5475 in Adults With Pulmonary Hypertension Associated with Chronic Obstructive Pu … Ended recruitment
  2022-501201-13-00 4 2023-03-01 Pulmonary hypertension associated with chronic obstructive pulmonary d
• A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy Ended recruitment
  2024-512785-33-00 10 2023-03-01 Active Idiopathic Inflammatory Myopathy (IIM)
• REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended recruitment
  2023-506924-94-00 5 2023-02-28 Cardiovascular disease
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L … Ended recruitment
  2024-511594-30-00 5 2023-02-23 Relapsed/Refractory Follicular Lymphoma
• A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin … Ended recruitment
  2024-518486-10-00 4 2023-02-23 Non-Muscle Invasive Bladder Cancer
• A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely … Ended recruitment
  2023-504719-34-00 5 2023-02-21 Moderate to Severly Active Ulcerative Colitis
• A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Thera … Ended recruitment
  2023-508104-38-00 4 2023-02-16 Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
• An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici … Ended recruitment
  2023-508740-21-00 4 2023-02-15 Non-Small Cell Lung Cancer
• A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants with Prodromal and Early Manife … Ended recruitment
  2023-503928-10-00 4 2023-02-01 Prodromal and Early Manifest Huntington’s Disease
• A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o … Ended recruitment
  2023-504277-20-00 5 2023-01-30 Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorde
• EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended recruitment
  2023-504832-16-00 4 2023-01-24 DIFFUSE LARGE B CELL LYMPHOMA
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics … Ended recruitment
  2023-510061-10-00 3 2023-01-09 Clear cell renal cell carcinoma (ccRCC, first-, second- and third-line
• Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut … Ended recruitment
  2024-511548-19-00 1 2022-12-13 Pancreatic Ductal Adenocarcinoma
• A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. Ended recruitment
  2023-504867-18-00 5 2022-12-05 Patients with Paroxysmal Nocturnal Hemoglobinuria
• Clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune … Ended recruitment
  2024-514147-28-00 5 2022-12-02 Primary immune thrombocytopenia
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended recruitment
  2023-509825-38-00 5 2022-12-01 Metastatic Non–Small Cell Lung Cancer

Showing 961–984 of 1,630 trials